JARISLOWSKY FRASER Ltd decreases its position in
Becton, Dickinson and Company (BDX), as an intrinsic calculation suggests it's 40% undervalued.
RBC Capital acknowledges a robust growth profile for BDX and raises its target. BDX experiences both a CFO transition and insider sell from
Michael Feld. A new immunology partnership with the
University of Pennsylvania invigorates valuation, and BDX raises its dividend for the 54th consecutive year. Despite year-to-date price declines, BDX's valuation amid
Morgan Stanley's positive outlook for the MedTech sector looks promising. Still, as BDX's earnings disappoint, an opportunity for long-term investment arises during recent share price rebound. Further, valuation potentials rise with launch of new cell analyzers and an alliance with
ChemoGLO for safety. Finally, a partnership with Certest Biotec on the menu expansion of the
BD MAX™ system introduces groundbreaking solutions driving connectivity across healthcare settings.
Becton Dickinson and BDX News Analytics from Thu, 03 Apr 2025 07:00:00 GMT to Sat, 03 Jan 2026 14:29:36 GMT -
Rating 3
- Innovation 5
- Information 7
- Rumor -3
